Valeritas (VLRX) & Its Rivals Head-To-Head Comparison

Valeritas (NASDAQ: VLRX) is one of 106 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it compare to its peers? We will compare Valeritas to related businesses based on the strength of its dividends, risk, valuation, analyst recommendations, earnings, profitability and institutional ownership.

Analyst Recommendations

This is a breakdown of current recommendations for Valeritas and its peers, as reported by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Valeritas 0 1 1 0 2.50
Valeritas Competitors 537 1984 3882 134 2.55

Valeritas presently has a consensus price target of $12.00, suggesting a potential upside of 733.33%. As a group, “Surgical & medical instruments” companies have a potential upside of 3.42%. Given Valeritas’ higher possible upside, equities research analysts plainly believe Valeritas is more favorable than its peers.


This table compares Valeritas and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Valeritas -225.97% -1,768.69% -90.30%
Valeritas Competitors -74.52% -78.80% -19.20%

Insider & Institutional Ownership

4.9% of Valeritas shares are owned by institutional investors. Comparatively, 46.6% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 1.2% of Valeritas shares are owned by insiders. Comparatively, 15.8% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Valeritas and its peers revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Valeritas $20.25 million -$49.30 million -0.17
Valeritas Competitors $1.51 billion $110.21 million -202.84

Valeritas’ peers have higher revenue and earnings than Valeritas. Valeritas is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

Valeritas has a beta of 4.45, suggesting that its share price is 345% more volatile than the S&P 500. Comparatively, Valeritas’ peers have a beta of 0.77, suggesting that their average share price is 23% less volatile than the S&P 500.


Valeritas peers beat Valeritas on 10 of the 13 factors compared.

Valeritas Company Profile

Valeritas, Inc. is a United States-based company, which is engaged in developing and commercializing treatment solutions that contribute to clinical outcomes for patients. The Company’s portfolio includes V-Go disposable insulin delivery device, which is distributed through retail pharmacy. Its V-Go delivers insulin at a continuous preset basal rate and bolus dosing for adults with Type 2 diabetes requiring insulin. Its development portfolio also includes the h-Patch technology, the Mini-Ject pre-filled needle-free delivery system and the Micro-Trans microneedle transdermal delivery patch. Its h-Patch is a controlled delivery technology platform designed to deliver drugs into subcutaneous tissue. The Mini-Ject represents needle-free injection system, combining a range of fully disposable pre-filled options. Micro-Trans microneedle array patch technology enables drug delivery into the dermis without limitations of drug size, structure, charge or the patient’s skin characteristics.

Receive News & Ratings for Valeritas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeritas and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit